Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Liposarcoma 8Hemangiosarcoma 8Fibrosarcoma 8Lymphoma, Large B-Cell, Diffuse 7Sarcoma, Synovial 6Rhabdomyosarcoma 6Neurofibrosarcoma 6Malignant mesenchymal tumor 6Leukemia 6Leiomyosarcoma 6Histiocytoma, Malignant Fibrous 6Hemangiopericytoma, Malignant 6Testicular Neoplasms 5Teratoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Testicular Germ Cell Tumor 4Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Endodermal Sinus Tumor 4Seminoma 3Neuroblastoma 3Neoplasm Metastasis 3Lymphoma, Follicular 3Hodgkin Disease 3Carcinoma, Embryonal 3

Interventions

Rituximab 2Epoetin Alfa 2Early Intervention, Educational 2Dexamethasone 2Darbepoetin alfa 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Vincristine 1Sucrose 1Prednisone 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Doxorubicin 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoproliferative Disorders × Ifosfamide × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡